Novo Nordisk posts strong sales and earnings growth for year to date

3 November 2021

Denmark-based diabetes care giant Novo Nordisk (NOV: N) today reported financial results, showing that n the first nine months of 2021 operating profit was 45.01 billion Danish kroner ($5.34 billion), an increase of 5% in kroner terms and up 12% at constant exchange rates (CER).

Net profit was up 12% at 36.87 million kroner, with diluted earnings per share of 15.98 kroner, a rise of 14%. Novo Nordisk’s shares were up 2.75% at 112.80 kroner pre-market.

Sales increased by 8% in kroner and by 13% at CER to 102.47 billion kroner. Sales in International Operations increased by 10% in kroner (13% at CER), and sales in North America Operations increased by 6% in kroner (13% at CER). Sales in the third quarter of 35.62 billion increased 15% in kroner (15% at CER) compared to the third quarter of 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK